India eyes dengue treatment rollout within five years as vaccine pipeline advances
India plans to roll out indigenous vaccines and treatment for dengue within the next three to five years. The country has recently approved a dengue vaccine and has several vaccine candidates in the pipeline, including an indigenous vaccine named DengiAll.
India plans to roll out indigenous vaccines and safe, affordable treatment for dengue within the next three to five years. The Drugs for Neglected Diseases initiative (DNDi) is working with partners in India to advance a pipeline of dengue treatments, including oral and injectable medicines. India's dengue vaccine pipeline includes an indigenous vaccine named DengiAll, developed by Panacea Biotec, which is undergoing Phase III clinical trials. The country has recently approved Takeda Pharmaceutical Company Ltd.'s tetravalent dengue vaccine, TAK-003, for use in people aged 4 to 60 years. India reported over 289,000 dengue cases in 2023, with experts warning that case counts are significantly underreported. The Dengue Alliance, a global partnership, is accelerating efforts to advance research and support the development of safe, accessible, and affordable treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.